All News
The third SARS-CoV-2 vaccine in IMID (RA, SpA, PsA, UC, CD) patients on immunosuppression improves the serologic response follow the first two vaccine doses and allowed them to close the gap compared to the two-dose vaccinated controls #EULAR2022 @RheumNow OP0192 Jyssum et al
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2022 POS0210
RNA sequencing in 11 RA-ILD patients vs 9 RA pts
⭐️Distinct gene expression in RA-ILD with type 1 IFN response, neutrophil activation, and degranulation and CCR1 chemokine interactions
@RheumNow
@fahidalghanim https://t.co/FIrZfzZV1C
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 OP0278:
Increase in risk of CVA compared to general population ~1.2x risk
⭐️This is unchanged between the pre-biologic (1972-1998) and the post-biologic treatment era
⭐️Interesting finding: smoking rate same over time in RA, despite decr in Norway in gen pop
@Rheumnow https://t.co/r8QsJABfvx
Eric Dein ericdeinmd ( View Tweet)
Charles-Schoeman et al. ORAL Surveillance. PE risk factors - History VTE, antidepressant use, obesity, steroids, male, age, OCP/HRT. PPI protective @RheumNow #EULAR2022 POS0239 https://t.co/fDLKrpvpgI
Richard Conway RichardPAConway ( View Tweet)
Can we predict VTEs from JAKi for RA at all?
Baseline elevated D-dimer pts who go on to develop VTE
(but not baseline CRP, so not just general inflamm)
Questions raised about effect modification for VTE following JAKi too. This story not yet done
OP0269 #EULAR2022 @RheumNow https://t.co/ErDcFpXXUl
David Liew drdavidliew ( View Tweet)
Leng et al. Tocilizumab biosimilar BAT1806/BIIB800 vs originator in MTX-IR RA. Not surprisingly they look the same. Great to see given negative clinical impact of recent supply problems with originator. @RheumNow #EULAR2022 POS0287 https://t.co/EqwINwcm7M
Richard Conway RichardPAConway ( View Tweet)
Long-term low-dose steroids for RA: can it be weaned?
Weaning after 2y of blinded add-on in RA:
either PNL 5mg/d or placebo
No substantial evidence of adrenal insufficiency
- symptoms same
- cortisol/ACTH same
It's never too late to wean the pred!
OP0270 #EULAR2022 @RheumNow https://t.co/jp2ZOlAEnb
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0274
Hospitalization for TB and other opportunistic infxn (OI) w inflamm joint disease:
⭐️9% with RA, 6% with PsA and AS in Western Australia
⭐️Decrease overall since 1985, but recent increase
⭐️Sharp rise of mycotic infections
⭐️No PJP, likely due to ppx
@Rheumnow
Eric Dein ericdeinmd ( View Tweet)
Yoshimura et al. 10 year findings of TOMORROW study. Glucocorticoid use of even 2mg/day is fracture risk in RA! @RheumNow #EULAR2022 POS0631 https://t.co/c8uCdPzUiE
Richard Conway RichardPAConway ( View Tweet)
RA & dementia - it's getting more damning
RA dementia risk: HR 1.25
from Korean nationwide data: RA n=138,592
this follows @MyasoedovaElena's data
RA systemic inflamm leading to dementia (AD, vascular)?
Need to understand if any DMARD protective
OP0271 #EULAR2022 @RheumNow https://t.co/4V7fOtVlnj
David Liew drdavidliew ( View Tweet)
#EULAR2022 OP0275: RA-ILD after transplant by @AARazmjou
⭐️UIP #1 cause RA-ILD, worst prognosis - 68% of transplanted pts
⭐️UIP seen in 88% of deceased patients, 56% of living
⭐️Median survival 5.3 years
@RheumNow https://t.co/tGBQ5GBlVg
Eric Dein ericdeinmd ( View Tweet)
#EULAR2022 OP0273
Difficult to treat RA (D2TRA):
⭐️Lower socioeconomic treatment
⭐️RF positivity
⭐️Higher inflammatory markers
⭐️ILD
⭐️Lower proportion on MTX, better response to JAKi and RTX
@RheumNow
Eric Dein ericdeinmd ( View Tweet)
GLORIA trial presented by Martin Boxers. 2 yr RCT, 5mg Pred vs. PBO shows DAS28 benefit (-0.37 to -0.62) & -1.7 better X-ray (vs PBO) at 2yrs. BUT signif more harm (AE) RR 1.24; mostly infx. Is this a good trade off? Abst# OP0263 #EULAR2022 https://t.co/kBiRYxXXZe
Dr. John Cush RheumNow ( View Tweet)
Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh
Dr. Antoni Chan synovialjoints ( View Tweet)
#EULAR2022 OP0276: What do patients want for preventative interventions for RA?
⭐️Survey of 1st degree relatives of RA pts (at risk) vs general pop were similar
⭐️'Hypothetical' treatment profile best aligned to abatacept
@Rheumnow https://t.co/r4y7SZbjTA
Eric Dein ericdeinmd ( View Tweet)
Survival of RA-ILD pts w/ lung 🫁 transplantation
Retrospective single centre study
*Mortality 36%
*Usual Interstitial Pneumonia worst prognosis w/ HR 7.13 (did not reach significance, small cohort)
*Survival time comparable to other lung Tx cohorts
#EULAR2022 OP0275 @RheumNow https://t.co/LslPxyXJCp
Aurelie Najm AurelieRheumo ( View Tweet)
EULAR 2022 – Day 2 Report
A full day at EULAR with oral and poster presentations of abstracts in the morning and a plethora of scientific (review) sessions in the afternoon. The latter covering topics like sarcoidosis, Still’s disease, fibromyalgia, back pain, sarcopenia, APS, IgG4 and imaging in vasculitis.
Read Article
Babies! Safety and Outcomes Data on Pregnancies
EULAR Congress 2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years.
Read Article
To contrast or not to contrast (in RA hand MRI?) POS0718 from #EULAR2022 showed good correlation between contrast/non-contrast imaging in synovitis, less so in tenosynovitis however. https://t.co/xL4XcRlIog
@RheumNow https://t.co/0cTep6MHLu
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Treat-to-target in RA is held with an almost religious fervour in rheumatology, but it's really hard to follow religiously. What happens if you're only T2T observant on the high holidays?
Answer: the world's not too bad!
(2y is bit short I realise)
POS0111 #EULAR2022 @RheumNow https://t.co/Boh74JmsP3
David Liew drdavidliew ( View Tweet)